PLIANT THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $55.65M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | After market close | – | $-0.38 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | After market close | – | $-0.82 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | $-0.95 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | $-0.92 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
Press releases
Announcements Pliant Therapeutics filed with the SEC
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Positive Long-Term Data from the
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Positive Long-Term Data from the
Other events · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF
Other events · EX-99.1 to Form 8-K
2023 © 2023 PLIANT THERAPEUTICS
Regulation FD disclosure · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K/A
Pliant Therapeutics Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Developing Novel Treatments for Fibrotic Diseases Corporate Presentation JANUARY 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K